AstraZeneca finally drops roxadustat US rights
The FibroGen AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat
FibroGen has now extended its clinical woes into a second month. After a phase 3 fail last month for Evrenzo dashed any remaining hopes of getting the oral anemia drug to market in the U.S., the biotech’s Duchenne muscular dystrophy (DMD) candidate has now flunked a late-stage study.
After an FDA rejection, commercial disappointments in Europe and Japan and a clinical trial flop, FibroGen and AstraZeneca’s oral anemia drug Evrenzo has finally found a win back in China.
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfaPlan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) --...
SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with...
Astellas is doing some house cleaning under new CEO Naoki Okamura, writing off assets before its full-year earnings report.
A day after the FDA raised safety concerns regarding a kidney disease candidate from GSK, the company did not end up with all green lights from an adcomm.
A patient with beta thalassemia or sickle cell disease—genetic disorders that affect the blood protein hemoglobin in red blood cells—currently has only two options for treatment. They can medicate the diseases’ many lifelong symptoms, or they can undergo a curative bone marrow transplant.